rna nanotechnology is a term that refers to the design, fabrication and use of nanoparticles that are mainly composed of rnas via bottom-up self-assembly. the packaging rna (prna) of the bacteriophage phi29 Dna packaging motor has been developed into a nanodelivery platform. this protocol describes the synthesis, assembly and functionalization of prna nanoparticles on the basis of three 'toolkits' derived from prna structural features: interlocking loops for hand-in-hand interactions, palindrome sequences for foot-to-foot interactions and an rna three-way junction for branch extension. sirnas, ribozymes, aptamers, chemical ligands, fluorophores and other functionalities can also be fused to the prna before the assembly of the nanoparticles, so as to ensure the production of homogeneous nanoparticles and the retention of appropriate folding and function of the incorporated modules. the resulting self-assembled multivalent prna nanoparticles are thermodynamically and chemically stable, and they remain intact at ultralow concentrations. Gene-silencing effects are progressively enhanced with increasing numbers of sirnas in each prna nanoparticle. systemic injection of the prna nanoparticles into xenograft-bearing mice has revealed strong binding to tumors without accumulation in vital organs or tissues. the prna-based nanodelivery scaffold paves a new way for nanotechnological application of prna-based nanoparticles for disease detection and treatment. the time required for completing one round of this protocol is 3-4 weeks when including in vitro functional assays, or 2-3 months when including in vivo studies. 
IntroDuctIon
RNA molecules can be manipulated as easily as DNA, with the difference that RNA has functions and structural versatility similar to those of proteins. These properties make RNA a suitable candidate to serve as building blocks for applications in nanotechnology and nanomedicine [1] [2] [3] [4] . The first proof of concept in the field of RNA nanotechnology was published in 1998 (ref. 5) , and this research field has since developed rapidly 1, 3, [5] [6] [7] [8] [9] [10] [11] . The rationale for using RNA as a nanomaterial is based on its unique features: (i) RNA is made up of a sugar-phosphate backbone chain with four ribonucleobases, adenine (A), guanine (G), cytosine (C) and uracil (U). Various combinations of the four nucleotides can result in nucleotide sequences with unique secondary structural viability [12] [13] [14] . (ii) The structural and folding properties of RNA structural motifs have been elucidated, which has laid the foundation for RNA nanoparticle construction 8, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The intermolecular (between RNA molecules) and intramolecular (within a RNA molecule) interactions of RNA tertiary motifs via both canonical and noncanonical base pairing, as well as base stacking, ensure the formation of stable RNA tertiary structures. (iii) RNA structural motifs and tertiary interactions can be isolated from known RNA structures available in public databases (e.g., Protein Data Bank) and can be used as building blocks in the rational design and grafting of RNA nanoparticles 17, 19, 25, 26 .
(iv) Small RNA molecules can be incorporated in RNA nanoparticles to add functionalities that regulate cell behavior. The finding that 98.5% of the human genome encodes noncoding RNA 27 has revolutionized the view of the role of RNA in cells. RNA molecules are actively involved in catalyzing biological reactions 28 , regulating gene expression [29] [30] [31] [32] and sensing or responding to cellular signals [33] [34] [35] . In recent years, a plethora of natural or artificial RNA molecules have been discovered or synthesized, including siRNA [36] [37] [38] [39] [40] [41] [42] [43] , ribozymes [44] [45] [46] [47] [48] , antisense RNAs 49, 50 , miRNAs 29, [51] [52] [53] , riboswitches 54, 55 and RNA aptamers [56] [57] [58] [59] [60] .
RNA nanoparticle construction, as described in this protocol, involves building-block extraction, rational nanoparticle design, and RNA nanoparticle fabrication and functionalization; the latter is performed concomitantly to nanoparticle assembly, functional assessment, characterization and utilization (Fig. 1) . RNA motifs extracted from known RNA structures can serve as building blocks for RNA nanoscaffold assembly. RNA tertiary structure interactions, including intermolecular and intramolecular interactions, as well as ion effects, are key considerations for assembly. Functional RNA molecules, such as siRNAs, miRNAs, ribozymes, riboswitches and RNA aptamers, can then be incorporated into the scaffold to functionalize RNA nanoparticles. Computational prediction of RNA folding and structure is an essential step for producing new structural designs [61] [62] [63] [64] [65] [66] . Available online resources include Mfold 67 , RNA designer 68 , Sfold 69 , NUPACK 70 and others 71 .
Because of its structural features, bacteriophage phi29 pRNA has been extensively used in the assembly of RNA nanoparticles (Fig. 2a) . pRNA forms a hexameric ring on the connector, and along with the viral protein gp16, which serves as ATPase to hydrolyze ATP, gears the phi29 DNA packaging motor to package the viral genome into the preformed procapsid 5, 72, 73 . Each pRNA contains a helical domain (5′ or 3′ paired ends denoted as the foot, Fig. 2b ) [74] [75] [76] [77] [78] [79] , a central domain (bases containing the right-and left-hand loops for intermolecular interactions 75, 76, 80, 81 (Fig. 2b) and a three-way junction (3WJ) motif (Fig. 2b) . Several techniques or toolkits (Fig. 3) that are based on pRNA structure (modular interaction and branch extension)
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells
Polymer-based nanoparticles. The advantages of using both natural and synthetic polymers include ease of construction, high structural stability, high drug encapsulation efficiency, high cellular uptake, improved drug-releasing rate, the ability to escape endosomes by way of protonation and the ease of modification to achieve multifunctional and targeted delivery 100, 101 . Major concerns for their use have been nonbiodegradability, insufficient biocompatibility, toxicity and the triggering of immunogenic reactions by the mononuclear phagocyte system 102 . Nevertheless, the development of biodegradable and biocompatible polymers has rendered possible a progress toward the clinical application of polymer-based nanodelivery systems 103 . Recently, 'smart' delivery vehicles, including thermosensitive 104, 105 and pH-sensitive 106 polymer nanoparticles, have been designed that improve the biocompatibility, in vivo pharmacokinetics and targeting efficacy of polymer nanocarriers. However, synthesizing uniform nanoparticles with defined structure and stoichiometry remains to be fully achieved.
Virus-based nanoparticles (VNPs). Viral particles are robust protein cages with homogeneous and well-defined geometry that effect active or passive cell entry, which makes them attractive structures for nanostructure fabrication. The viral genome can be relatively easily manipulated, and the viral particles can be modified and conjugated with active biomolecules or chemical groups 107, 108 . Although most of the VNPs are not typically human pathogens, reliable methods to inactivate replicating viruses or convert replicating viruses to virus-like particles need to be standardized in order to ensure the safety of the in vivo application of VNPs. Substantial concerns exist regarding the possible incorporation of the viral genome into host chromosomes, as well as its possible toxicity, immunogenicity and biodistribution.
Inorganic nanoparticles.
Inorganic nanoparticles can be carbonbased, metal-based and semiconductor-based 109 . Most inorganic nanoparticles have been developed for use in medical imaging because of their brightness, high contrast and photostability 110 . Some of them have great potential for photothermal therapy. However, biological incompatibility, toxicity, nondegradability and entrapment of the inorganic nanoparticles by the lung, liver and kidney are major disadvantages of their clinical application.
DNA-based nanoparticles. DNA nanotechnology has great potential for diverse applications. This technology uses the complementarity patterns of the four bases in DNA to construct a variety of nanostructures and nanomachines 111 . Constructed
Design pRNA nanoparticles based on pRNA structural features; determine the required RNA sequences; design DNA primers DNA nanoparticles include individual folding structures [112] [113] [114] [115] , tile-shaped structures [116] [117] [118] and dynamic assemblies [119] [120] [121] [122] [123] .
A large number of reports on DNA nanotechnology have been published over the years 112, [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] . Most of the DNA nanostructures have been used as templates to direct and support the assembly of other nanoarchitectures [134] [135] [136] [137] [138] [139] [140] . DNA nanoparticles can be functionalized by quantum dots 141 , DNA aptamers 142 or other functional molecules. One example of medical applications of DNA nanoparticles involves the use of a DNA nanostructure to cage an enzyme that could be released to induce cell apoptosis 143 . However, in comparison with RNA nanotechnology, the use of pure DNA nanoparticles for clinical application is limited by their relative structural and functional simplicity ( Table 1) .
RNA-based nanoparticles. The RNA nanoparticles described in this protocol have many favorable attributes:
They have defined size, structure and stoichiometry. The size of pRNA nanoparticles can be easily controlled by the primary RNA sequence, as it determines the global folding and size of each RNA subunit, or by making use of tertiary interactions that are designed to control the assembling stoichiometry of the RNA nanoparticles. The hand-in-hand interactions via interlocking loops (toolkit I, Fig. 3a) , foot-to-foot interactions via palindrome sequences (toolkit II, Fig. 3b ) and branch extension (toolkit III, Fig. 3c,d ) can help the pRNA nanoparticles grow into different oligomers in a controllable manner. Thus, unpredictable side effects, such as off-target activity and in vivo toxicity, which may arise from the heterogeneity of particles, can be avoided 1, 3, 90, 91, 144 . The nanoscale size and branched ratchet shape of our RNA nanoparticles facilitate tumor penetration and enable them to take advantage of the enhanced permeability and retention effect, through which some nanoparticles tend to accumulate preferentially in cancerous tissues with respect to healthy tissues. Nonspecific cell entry can be avoided, as it is unfavorable for the polyanionic RNA to cross the negatively charged cell membranes [145] [146] [147] [148] . RNA nanoparticles are highly soluble, homogeneous and are not prone to aggregation. They do not need to be linked to PEG or serum albumins in order to increase their aqueous solubility or stability 1, 144 . The multivalent nature of RNA nanoparticles enables their facile functionalization for simultaneous targeting and/or delivery of additional therapeutic and targeting ligands for achieving synergistic effects 91 . Chemically modified RNA is resistant to RNase degradation and retains correct folding and biological functions 90, 91, 149 . RNA nanoparticles can be thermodynamically stable; therefore, the entire construct can remain intact in the body at ultra-low concentrations 90, 91 .
RNA-based nanoparticles have favorable pharmacokinetic and pharmacodynamic profiles in vivo 150 . Systemic injection of thermodynamically and chemically stable RNA nanoparticles into mice has revealed that the RNA nanoparticles strongly and specifically bind to cancer cells without accumulating in vital organs or tissues 90, 91, 150 . This protein-free system induces minimum host-immune responses that will allow multidose treatment of cancer and other chronic diseases. This approach is particularly applicable to patients who produce neutralizing antibodies in response to protein-based reagents. Economically viable, industrial-scale production by enzymatic transcription is possible in a cell-free system. Modular design allows self-assembly of engineered RNA fragments 1, 144 . RNA is classified as a chemical reagent by the US Food and Drug Administration; therefore, the regulatory approval process in the United States is expected to be easier for RNA-based nanoparticles than for protein-based clinical reagents 1, 144 .
Potential applications
Owing to their multivalency, RNA nanoparticles can harbor a variety of functionalities in different combinations to achieve the desired purpose. The size of pRNA-based nanoparticles is ideal for passive delivery into tumors via the enhanced permeability and retention effect, which minimizes the off-target effects or toxicity in vivo. Studies conducted over the past decade or so have demonstrated that the size of the nanoparticles is a crucial
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Toolkit III determinant of their in vivo behavior. If the size is smaller than 10 nm, the nanoparticles are likely to diffuse nonspecifically into normal tissue and organs and cause off-target effects; if the size is larger than 100 nm, the nanoparticles are less likely to enter the cells by receptor-mediated endocytosis and more likely to be trapped into the liver and lung, thereby stimulating microphage activity and causing organ toxicity [151] [152] [153] . Active delivery of RNA nanoparticles can be achieved by introducing targeting moieties into them. These functionalized RNA nanoparticles, with the combination of detection molecules, 83, 89, 91 . In addition, the assembled RNA nanoscaffold can be potentially used to achieve the spatial organization of enzymes and/or proteins to reconstitute metabolic pathways 25 , as well as in the construction of biosensors for various applications 154, 155 .
Limitations
The sensitivity of RNA to RNase degradation and its potential dissociation because of the noncovalent nature of the link that holds self-assembled RNA quaternary structures together has prompted many scientists to shy away from RNA nanotechnology. However, chemical modification of the RNA ribose ring, such as 2′-fluorine (2′-F) modification, has been introduced as a successful strategy for increasing RNA resistance to RNase degradation [156] [157] [158] [159] [160] [161] . Furthermore, the finding that certain chemically modified RNAs preserve their folding properties and original biological function implies the feasibility of RNA nanotechnology with diverse applications 149 . Another key challenge for in vivo application of RNA nanoparticles is the dissociation that occurs in very dilute in vivo conditions after systemic injection. This tendency is no longer a concern, however, as demonstrated in the recent finding that the pRNA 3WJ core and its derivative are thermodynamically stable and resistant to denaturation; further, they remain intact at ultralow concentrations after systemic injection 90, 91 .
Some other limitations to the use of RNA nanoparticles include size limitations of industrial-scale synthesis of chemically modified RNA (typically the length of these RNAs that can be practically produced is less than 80 nt), cost of chemically synthesized RNA nanoparticles and endosome escape of RNA nanoparticles after cell entry. The cost and size limitations can be overcome with time as the technology develops further. Incorporation of endosome-disrupting reagents [162] [163] [164] [165] might improve endosome escape of RNA nanoparticles. Figure 1 shows the workflow of this protocol. When you are implementing the PROCEDURE, please be aware that, as mentioned above, the functionalization of the RNA nanoparticles (Steps [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is achieved concomitantly with RNA nanoparticle assembly. Therefore, the types, functions and number of functionalities to be fused to the RNA nanoparticles need to be established before nanoparticle and DNA primer design (Reagent Setup).
Experimental design
This protocol is modular in nature, and, depending on specific experimental requirements, any number (from zero to five) of the five functionalizations covered in the PROCEDURE and described in sequential Steps 11-20-incorporation of siRNAs, RNA aptamers, RNA ribozymes, targeting ligands and fluorophores-can be implemented in no prespecified order. Similarly, the RNA nanoparticle characterization approaches described (Steps 21-31) are mutually independent procedural 'modules', some or all of which can be implemented, keeping in mind that the order in which they are performed is unimportant. In general, for good RNA nanoparticle characterization, we recommend implementing at least one mutually alternative characterization experiment in each step (Steps 21-31). Tables 2 and 3 . Introduce a T7 promoter 
MaterIals
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• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 2′-deoxy, 2′-fluoro cytosine 5′-• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • sequence (5′-TAATACGACTCACTATA-3′) at
6|
Centrifuge the sample at 16,500g for 30 min at 4 °C, remove the supernatant, wash the pellet with 70% (vol/vol) ethanol once and then dry the pellet for 5 min using a SpeedVac.
7|
Resuspend the pellet in 20 µl of 0.05% (vol/vol) DEPC-treated water (5× concentrated).  pause poInt The DNA template can be stored at −20 °C in the short term (6 months) or at −80 °C for the long term (1 year or more).
8| (Optional) If you plan to synthesize 2′-F-modified RNA, the DNA template will have to be of high quality. In this case, run the DNA products from the PCR in a 2% (wt/vol) Synergel-agarose gel using the conditions detailed in Step 4. Cut the band of interest under UV light and extract the PCR DNA template from the gel using the QIAEX II gel extraction kit (following the manufacturer's guidelines). If necessary, concentrate the template to obtain at least 0.5 µg µl − 1 of amplified DNA template. Please note that if the DNA PCR products show specific and clean bands in the agarose gel (Step 4), then an alternative to additional gel purification steps is to pass DNA through NucAway spin columns, according to the manufacturer's guidelines, to remove free nucleotides and salts. ! cautIon UV light is harmful to the eyes; wear protective goggles or use a shield while you are performing the experiments.  crItIcal step The purity and quantity of DNA used for 2′-F transcription are crucial. The amount of DNA template needed for a typical 20-µl transcription reaction is at least 1 µg.  pause poInt The DNA template can be stored at −20 °C in the short term (6 months) or at −80 °C for the long term (1 year or more). (254 nm). Elute the RNA from the gel at 37 °C using RNA elution buffer (2 h for the first elution and 2 h for the second). Please note that the passive elution just described can be replaced by an electro-elution step by using the Elutrap electroelution system according to the manufacturer's guidelines.
In vitro rna synthesis
( assembly of thermodynamically stable rna nanoparticles using toolkits • tIMInG ~1 week  crItIcal When you are following pRNA nomenclature 169 , please note that the right-hand (R-loop) sequence is assigned an uppercase letter (i.e., A, B, …) and the left-hand (L-loop) sequence is assigned a lowercase letter with a prime (i.e., a′, b′, …). A pair of the same letters, one uppercase and one lowercase (e.g, Aa′), designates a complementary sequence in the R/L interlocking loop, whereas different letters indicate a lack of interlocking sequence complementarity.
To distinguish from the wild-type pRNA, 'Ex' is added before the letters (e.g., ExAa′) to indicate that the interlocking looploop interaction is extended (Fig. 3a) . The 3WJ domain of phi29 pRNA is constructed using three RNA oligos, denoted as a 3WJ , b 3WJ and, c 3WJ . The three branches are named H3-1, H3-2 and H3-3, respectively (Fig. 3c) . The 3WJ-derived X-shaped pRNA is constructed using four RNA oligos denoted as a X , b X , c X and c 3WJ . The four branches are named H4-1, H4-2, H4-3 and H4-4, respectively (Fig. 3d) .
10| Assemble the nanoparticles according to option A to construct RNA nanoparticles via hand-in-hand interactions ( Fig. 4a-e) . Use option B, to achieve modular assembly using foot-to-foot interactions (Fig. 4 f-j) , or use option C to assemble them by branch extension (Fig. 4k-n) .
(a) assembly of rna nanoparticles via hand-in-hand modular design (i) Construct the loop-extended pRNAs by replacing the 4-nt loop complementary region of the wild-type pRNA R-and L-loops with a series of extended loop sequences (table 4).  crItIcal step As altering the nucleic acid sequences might affect the global folding of pRNA molecules, the pRNA with re-engineered loop sequences should be thoroughly analyzed with an online RNA-folding program, such as Mfold 67 . (ii) Design RNA sequences using re-engineered loop-loop interactions (table 4): pRNA dimer (ExAb′-ExBa′), trimer (ExBa′-ExCb′-ExAc′), tetramer (ExBa′-ExCb′-ExDc′-ExAd′), pentamer (ExBa′-ExCb′-ExDc′-ExFd′-ExAf′), hexamer (ExBa′-ExCb′-ExDc′-ExEd′-ExFe′-ExAf′) and heptamer (ExBa′-ExCb′-ExDc′-ExEd′-ExFe′-ExGf′-ExAg′). Design the primers according to the instructions in Reagent Setup and synthesize RNA strands by following Steps 1-9 of the PROCEDURE. (iii) Mix the required monomeric subunits to assemble hand-in-hand pRNA polyvalent nanoparticles in an equimolar ratio in TMS buffer. Incubate the mixture at 37 °C for 1 h and assay the formation of RNA complexes via 6% (wt/vol) native PAGE gel run in TBM buffer at 80 V for 3-4 h at 4 °C. (iv) Purify the hand-in-hand assemblies by 6% (wt/vol) native PAGE gel run in TBM buffer. Excise the band corresponding to each assembled multimer (dimer, trimer, tetramer, pentamer, hexamer or heptamer, respectively), and elute the RNA using the RNA elution buffer in the presence of 10 mM Mg 2 + . Precipitate the RNA as in Step 9A(v,vi) and rehydrate the pellet in TMS buffer.
? troublesHootInG  pause poInt The RNA nanoparticles obtained can be stored at −20 °C for the short term (1 month) or at −80 °C for the long term (6 months).
(b) assembly of rna nanoparticles via foot-to-foot modular design
(i) A palindrome sequence reads the same way in the 5′-to-3′ direction on one strand as in the 5′-to-3′ direction on a complementary strand. Design the 6-nt palindrome sequences according to Fig. 3b , and introduce the palindrome sequence at the 3′ end of the RNA building blocks to bridge RNA nanostructures, motifs or scaffolds for self-assembling RNA hexamers, octamers, decamers and dodecamers or any other duplex with an even number of subunits. (ii) Extend the 3′ end of ExAb′ with a palindrome sequence (5′-CGAUCG-3′) to construct foot-to-foot RNA complexes. Design the primers according to the instructions in Reagent Setup, and synthesize RNA strands by following Steps 1-9 of the PROCEDURE. (iii) Introduce an ExAb′ subunit with a 3′-overhanged palindrome sequence into trimer (ExBa′-ExCb′-ExAc′), tetramer (ExBa′-ExCb′-ExDc′-ExAd′), pentamer (ExBa′-ExCb′-ExDc′-ExFd′-ExAf′), hexamer (ExBa′-ExCb′-ExDc′-ExEd′-ExFe′-ExAf′) and heptamer (ExBa′-ExCb′-ExDc′-ExEd′-ExFe′-ExGf′-ExAg′) sequences at an equal molar ratio in TMS buffer. Incubate the mixture at 37 °C for 1 h, and assay the formation of RNA complexes using 4% (wt/vol) native PAGE gel run in TBM buffer at 80 V for 4-5 h at 4 °C. (iv) Purify the foot-to-foot assemblages by 4% (wt/vol) native PAGE gel run in TBM buffer. Excise the band corresponding to each assembled foot-to-foot constructs (twin dimer, twin trimer, twin tetramer, twin pentamer, twin hexamer or twin heptamer, respectively) and elute the RNA using RNA elution buffer in the presence of 10 mM Mg 2 + . Precipitate the RNA as in Step 9A(v,vi), and rehydrate the pellet in TMS buffer.  crItIcal step The assemblage of the hand-in-hand and foot-to-foot nanostructures requires the presence of at least 5 mM Mg 2 + . Add Mg 2 + into the RNA elution buffer to ensure structural integrity during the purification process. Keep the purified products in TMS buffer when storing.  pause poInt The RNA nanoparticles obtained can be stored at −20 °C for the short term (1 month) or at −80 °C for the long term (6 months). (c) assembly of rna nanoparticles by branch extension (i) Construct the 3WJ domain by mixing together the three RNA oligos denoted as a 3WJ , b 3WJ and c 3WJ at a 1:1:1 molar ratio in 0.05% (vol/vol) DEPC-treated water or TMS buffer. Load the resulting solution onto a 15% (wt/vol) native PAGE gel and run the gel in TBM buffer at 100 V and 4 °C for 1-2 h to purify the complex. The assembly of 3WJ domain from three RNA oligos is highly efficient, as long as the three RNA oligos were mixed in equal molar ratio. Only one major band from 3WJ will appear, and it will run slightly ahead of xylene cyanol. Excise that band from the gel and elute the RNA in RNA elution buffer for ~4 h at 37 °C, followed by ethanol precipitation overnight.
Rehydrate the dried pellet in DEPC-treated water or TMS buffer. (ii) Analyze the formation of the complexes using 15% native PAGE or 8 M urea PAGE gel in TBM running buffer. After running the gel at 100 V and 4 °C for 3 h, visualize the RNA by ethidium bromide or SBYR Green II staining. (iii) Construct the pRNA-X motif by opening the R-loop of the pRNA subunit and inserting a 9-bp sequence, thereby forming a double-helical segment (H4-2), and extending the H4-3 helix by 4 bp. The X-shaped motif can then be assembled from four RNA oligos, denoted as a X , b X , c X and c 3WJ . Mix the four RNA oligos in a 1:1:1:1 ratio in the absence of metal salts. For the detailed assemblage procedure, please refer to Step 10C(i, ii).  pause poInt The RNA nanoparticles obtained can be stored at −20 °C for the short term (3 months) or at −80 °C for the long term (1 year).
construction and assay of rna nanoparticles fused with sirna • tIMInG ~1 week  crItIcal Please note that, as mentioned in the Experimental design (INTRODUCTION), the subsections covered by Steps 11-20 are procedural modules. None, some or all of these can be implemented, in no prespecified order, depending on the needs of the experimenter.
11|
Design siRNA-fused RNA nanoparticles by keeping in mind the following principles: altering the primary sequences of the 5′-or 3′-end helical region of an RNA nanoparticle does not affect the structure and folding of the RNA, as long as the two strands are paired 77 ; furthermore, extensive studies have revealed that double-stranded siRNAs are able to replace the helical region in RNA nanoparticles and retain their function 82, 83, [88] [89] [90] [91] . The siRNA sequences can be separated from the scaffold sequences by introducing an AA or UU bulge on the double-helical strands. The 3′-end 2-nt overhang of the siRNA should be kept for Dicer recognition, binding and further processing. To assay the incorporated siRNA function, also design a negative-control siRNA that is to be compared with the active siRNA component. Two kinds of negative-control siRNA designs exist: one consists of a point mutation along the siRNA sequence and the other is a scrambled design that makes use of siRNA Wizard (http://www.sirnawizard.com/). After the design is complete, synthesize the siRNA-fused RNA nanoparticles according to Steps 1-10.
12|
Assay the efficacy of the RNA nanoparticles fused to siRNAs that are designed to knock down a fluorescent reporter (option A), a luminescent reporter (option B) or an anti-apoptotic factor (option C). (ii) At 24 h after seeding, check cell confluence, and once the cells are 70-80% confluent, co-transfect them with RNA nanoparticles harboring firefly luciferase siRNA (or RNA nanoparticles harboring negative-control firefly luciferase siRNA) with both plasmid pGL3 coding for firefly luciferase and pRL-TK encoding renilla luciferase by Lipofactamine 2000 transfection reagent (follow manufacturer's guidelines). pRL-TK encoding renilla luciferase serves as an internal control to normalize the luciferase data. (iii) At 24 h after transfection, use the dual-luciferase reporter assay system to assay the firefly luciferase activity after fusion with the RNA nanoparticle (follow manufacturer's guidelines). Briefly, wash cells once with PBS and lyse them with passive lysis buffer. Shake the plates for 15 min at RT. Add 20 µl of lysate to 100 µl of luciferase assay reagent (LAR II) to Microfluro 1 96-well white microtiter plates, and then measure firefly luciferase activity by using Synergy 4 microplate reader. Upon addition of 100 µl of Stop & Glo reagent, obtain control measurements of renilla luciferase activity. Normalize the previously obtained data with respect to the renilla activity to determine the average ratio of firefly-to-renilla luciferase activity over several trials (Fig. 5) . (iv) (Optional) Owing to the multivalency of the RNA nanoparticles, multiple copies of siRNA targeting the same loci within one gene, or different siRNAs targeting different loci within one gene, can be applied to one RNA nanoparticle to generate enhanced gene knockdown effects. The dual-luciferase report assay system can also be used to assay the enhanced siRNA-targeting effects toward the gene encoding firefly luciferase 91, 169 (Fig. 6) . Electrophoretically transfer the protein to Immun-Blot PVDF membranes using a Trans-Blot SD semi-dry transfer cell. Probe the membrane with human-specific survivin antibody (1:4,000 dilution) and β-actin-specific antibody (1:5,000 dilution) overnight, followed by 1:10,000 goat anti-rabbit IgG and an HRP-conjugated secondary antibody for 1 h. Blot the membrane using Immobilon western chemiluminescent HRP substrate and expose it to film for autoradiography.
construction and in vitro assay of rna nanoparticles fused to rna aptamers • tIMInG 3-4 d 13| Similar to antibodies, RNA aptamers selected from the systematic evolution of ligands by exponential enrichment (SELEX) [56] [57] [58] [59] [60] can bind specific targets, including proteins, organic compounds and nucleic acids [173] [174] [175] . Design suitable aptamers for your own objectives, keeping in mind that aptamers can be linked to the 3′ and 5′ ends of the RNA scaffold and that, to facilitate independent folding, polyU or polyA linkers can be placed between the RNA scaffold and the aptamer. After design, synthesize the aptamer-fused RNA nanoparticles according to PROCEDURE Steps 1-10.
14|
Assay the function of aptamer-fused RNA nanoparticles by fluorescence emission (option A), a property that can be used for in vivo tracking (Fig. 5c) ; cell binding (option B), which can be used as a way to define targets for delivery; or ligand binding (option C), which can be exploited for the purification of RNA nanoparticles (Fig. 5d) . (iv) Elute the RNA with 50 µl of 5 mM biotin in STV-binding buffer; the elution step can be repeated twice (elutions 1 and 2 ). Analyze the sample fractions (RNA before loading, pass-through, washes 1-7 and elutions 1 and 2) by native PAGE run in TBM buffer and visualize them with ethidium bromide staining (Fig. 5d) .
construction and assay of rna nanoparticles harboring ribozymes • tIMInG 1 d 15| RNA ribozymes (RNA enzymes) have the ability to catalyze chemical reactions 44, 48 , cleave mRNA and regulate gene expression at the post-transcriptional level. In particular, an anti-HBV ribozyme cleaves the genomic RNA of the hepatitis B virus (HBV) genome 84 . An RNA nanoparticle fused with this ribozyme is able to cleave the 135-nt HBV RNA genome substrate into two fragments of 60 nt and 75 nt, respectively 84, 90 (Fig. 5e) . RNA nanoparticles that harbor anti-survivin ribozymes, on the other hand, target the anti-apoptosis factor survivin and downregulate genes involved in tumor development and progression 86 . Design suitable ribozymes to be fused to your RNA nanoparticle by keeping in mind that ribozymes can be linked to the 3′ and 5′ ends of the RNA scaffold. To facilitate independent folding, polyU or polyA linkers can be placed between the RNA scaffold and the ribozyme. Synthesize ribozyme-fused RNA nanoparticles by following PROCEDURE Steps 1-10. Please note that two 'anti-HBV ribozyme' nanoparticles should be synthesized: one that contains the active ribozyme-the positive control 84 -and one in which the fused ribozyme has one point mutation that abolishes its function, which serves as a negative control. See (Fig. 5f) .  crItIcal step To ensure sufficient binding, the cells need to be kept in a folate-free medium for at least 12 h before the binding assay.
? troublesHootInG construction of rna nanoparticles harboring imaging molecules • tIMInG 3-4 d 20| Many different strategies have been developed to achieve co-transcriptional (option A) or post-transcriptional (options B, C and D) labeling of RNA molecules. These labeling strategies have been shown to be highly efficient for the preparation of long-chain RNAs 169, 179, 180 , and they can be distinguished according to whether they implement single-molecule labeling (options A, B and C) or random labeling of the whole RNA chain (option D). Co-transcriptional labeling is easy to perform, but the yield of labeled products cannot be guaranteed. Use this approach for experiments that only require a small amount of labeled RNA. Post-transcriptional labeling of single-stranded RNA can be implemented for large-scale RNA labeling; however, it is a multistep process that is performed under harsh conditions, and thus this approach may damage RNA strands. Use this method with chemically modified, stable RNA strands. The post-transcriptional, whole-chain labeling approach is suitable for RNA strands whose function does not depend on folding.
(v) (Optional) Label SH-RNA with Cy3 maleimide monoreactive dye: Dissolve 1 mg of Cy3 maleimide monoreactive dye in 100 µl of DMSO as a dye stock solution. Please note that this dye stock solution is only stable with good reactivity for up to 2 weeks at −20 °C. To confer −SH reactivity to the modified RNA, add 10 mM DTT to the labeled RNA from the previous step to cleave (reduce) disulfide bonds. Incubate the mixture at RT for 30 min. Use a desalting column to remove the DTT and adjust the pH of the RNA solution with PBS buffer. Add 100 nmol Cy3 maleimide monoreactive dye into the RNA, and allow the reaction to proceed for 2 h at RT. Ethanol-precipitate and purify the final labeling products via 8% (wt/vol) urea-PAGE. (D) Whole-chain labeling of rna nanoparticles (i) Achieve post-transcriptional fluorescent labeling of the RNA molecule using functionalized fluorophores harboring a mono-alkylating reactive group, as developed by Mirus. Label the RNA strand using Label IT nucleic acid labeling kits according to the manufacturer's guidelines.  crItIcal step Whole-chain RNA labeling may cause misfolding and loss of function of the RNA strands. The region of the RNA strand that is to be labeled should, therefore, be carefully considered. It is better to introduce whole-chain labels in the RNA strands that are responsible for assembling RNA scaffolds but that have no functional role.  crItIcal step During all procedures for Cy3 labeling, the reaction flask should be shielded from light. 3 M sodium acetate should be prepared at pH 6.5, as Cy3 rapidly degrades in more acidic pH.
? troublesHootInG assessment of the successful assembly of rna nanoparticles • tIMInG 3-4 d  crItIcal Please note that, as mentioned in the Experimental design (INTRODUCTION), the subsections that cover Steps 21-31 are procedural modules. Some or all of these can be implemented, in no particular order.
21|
Assay the assembly of RNA nanoparticles by native PAGE (option A) for quick validation of desired products or by atomic force microscopy (AFM; option B) for detailed structural characterization of RNA nanoparticles (Fig. 4) . (a) assay the assembly of rna nanoparticles by native paGe (i) A simple and easy way to assay the assembly of RNA nanoparticles is by gel-shift assays. Visualize the corresponding bands as described in Step 10A(iii). (b) assay the assembly of rna nanoparticles by aFM (i) Synthesize 1-(3-aminopropyl) silatrane according to the procedures described by Shlyakhtenko et al. 183 and Lyubchenko and Shlyakhtenko 183 . Incubate freshly cleaved mica with 167 nM 1-(3-aminopropyl) silatrane to generate 1-(3-aminopropyl) silatrane-coated mica 183, 184 . (ii) Dilute the RNA samples with TMS buffer to a final concentration of 3-5 nM. Deposit a droplet of the sample (5-10 µl)
immediately on the 1-(3-aminopropyl) silatrane-coated mica. After 2 min of incubation on the surface, wash off the excess sample using DEPC-treated water, and dry it with a flow of argon gas. (iii) AFM images in air can be acquired using a MultiMode AFM NanoScope IV system operating in tapping mode. concentrations of urea (0, 2, 4 and 6 M). Load the samples onto a 16% (wt/vol) native PAGE gel for visualization with a Typhoon FLA 7000 under the Cy3 channel (Fig. 7b) (Fig. 7d) .
assessing in vivo tumor targeting of prna nanoparticles • tIMInG 1-2 months ! cautIon In vivo studies can only be conducted in accordance with appropriate institutional regulatory board guidelines. All relevant permissions must be obtained before performing any experiment.
27| Keep 6-week-old male nude mice (nu/nu) on a folate-free diet for a total of 2 weeks before the experiment.  crItIcal step If you are using folate as the targeting molecules for delivery, keeping mice on a folate-free diet will free the folate receptor from folate and avoid the competitive binding of free folate to the folate receptor, which will ensure the success of the in vivo targeting assay. 
28|
30|
Once the tumors grow to ~500 mm 3 (for KB cell-based xenografts, it usually takes ~10 d), inject the mice i.v. through the tail vein with a single dose of 600 µg of 2′-F U/C-modified folate Alexa Fluor647-labeled pRNA nanoparticles (~15 nmol in PBS buffer, equal to 24 mg kg − 1 ).  crItIcal step All RNA nanoparticles used for in vivo studies must be chemically modified (2′-F) in order to increase their stability in vivo. Otherwise, unmodified RNA will be degraded by ribonucleases in plasma immediately upon injection.
To evaluate the targeting, the RNA nanoparticles should be labeled with a far-red or near-IR dye, such as Alexa 647, for better signal penetration and low background noise.
31| At 24 h after injection, perform whole-body imaging with an IVIS Lumina Station, with the body of the mouse lying sideways in the imaging chamber (Fig. 8) .
32| After whole-body imaging, euthanize the mouse by CO 2 asphyxiation followed by cervical dislocation. Dissect and image the tumors, liver, spleen, heart, lung, intestine, kidney and skeletal muscles of the mouse individually. ? troublesHootInG Troubleshooting advice can be found in table 5.
• tIMInG Steps 1-8, amplification of the DNA template via PCR: ~1 d
Step 9, in vitro RNA synthesis: 2-3 d
Step 10, assembly of thermodynamically stable RNA nanoparticles using toolkits: ~1 week Steps 11 and 12, construction and assay of RNA nanoparticles fused with siRNA: ~1 week Steps 13 and 14, construction and in vitro assay of RNA nanoparticles fused to RNA aptamers: 3-4 d Steps 15-18, construction and assay of RNA nanoparticles harboring ribozymes: 1 d
Step 19, construction of RNA nanoparticles harboring targeting ligands: 3-4 d
Step 20, construction of RNA nanoparticles harboring imaging molecules: 3-4 d
Step 21, assessment of the successful assembly of RNA nanoparticles: 3-4 d
Step 22, determination of RNA nanoparticle hydrodynamic radius: 1 d
Step 23, determination of RNA nanoparticle melting temperature: 1-2 d
Step 24, assessment of the thermodynamic stability of RNA nanoparticles: 1-2 d Steps 25 and 26, assay to determine the chemical stability of RNA nanoparticle: 2-3 d
Steps 27-32, assessing in vivo tumor targeting of pRNA nanoparticles: 1-2 months, depending on how long it takes to establish tumor xenografts
antIcIpateD results
This protocol provides detailed procedures for constructing RNA nanoparticles using the unique structural features of bacteriophage phi29 pRNA. A series of assembly toolkits can be used to assemble a variety of multivalent nanoparticles.
We have also provided comprehensive methods for functionalizing pRNA nanoparticles with targeting, detection and Introduce whole-chain labeling to the RNA strands only for assembling RNA scaffolds. Otherwise, end-labeling methods should be considered therapeutic compartments (Fig. 1) . Conjugation of functionalities is achieved before, not after the assembly of the RNA nanoparticles, thus ensuring the production of homogeneous nanoparticles with appropriate folding and function after fusion. Anticipated results of this protocol are as follows:
The resulting RNA nanoparticles will be homogeneous and can be manufactured with high reproducibility and known stoichiometry 90, 91 . The resulting RNA nanoparticles will be chemically and thermodynamically stable and will remain intact at ultralow concentrations (160 nM, as shown in Fig. 7c ) 90, 91 . The diameter of resulting RNA nanoparticles typically will be in the 10-50 nm range, which is an optimal size for greatly improving the in vivo pharmacokinetics, pharmacodynamics, biodistribution and toxicology profiles 90, 91, 150 . Cell type-specific gene targeting can be achieved via target delivery modules, which reduce off-target toxicity and lower the concentration of the drug administered, thus reducing the adverse effects of the therapeutics 150 .
The main advantageous characteristics of these pRNA-based nanoparticles are the following: Protein-free RNA nanoparticles that contain RNA aptamers that target specific receptors can have a higher specificity than their protein counterparts, while having a lower antibody-inducing activity. These characteristics provide an opportunity for repeated administration and thus for treatment of chronic diseases 150 . RNA nanoparticles have a modular design, and thus they can self-assemble via a bottom-up approach to harbor multiple therapeutic reporters and/or targeting payloads in order to achieve enhanced or synergetic effects [82] [83] [84] [85] [86] [87] [88] [89] [89] [90] [91] .
We have shown that RNA nanoparticles that harbor different functional modules retain their folding and independent functionalities for specific cell binding, cell entry, gene silencing, catalytic function and cancer targeting, both in vitro and in animal trials 90, 91 . Systemic injection of the thermodynamically and chemically stable RNA nanoparticles into mice revealed that the RNA nanoparticles strongly and specifically bind to cancers without accumulating in the liver, lungs or any other vital organ or tissue (Fig. 8 ) 90, 91, 150 . 
